Neil Josephson

Neil Josephson is the Chief Medical Officer at Iambic Therapeutics, an AI-driven drug discovery company. A physician-scientist trained in oncology and hematology at Columbia University, he has extensive experience leading clinical development. He previously held senior roles at Zymeworks and Seagen, where he led successful programs for HER2-targeted therapies and Hodgkins Lymphoma.

Before entering the biopharmaceutical industry, he served as an Associate Professor of Medicine at the University of Washington, where he remains a Clinical Associate Professor. He has also publicly committed to the role of physicians in discussing public health topics, including firearm safety, with patients when risk factors are present.

He is now leading a clinical trial at Iambic that involves a combination with zanidatamab, the same HER2-targeted bispecific antibody whose development he led at his former company, Zymeworks.